Niche Opportunity Target the ESRD and chronic kidney disease pruritus space with a once-daily oral transmucosal film; emphasize fast onset, high bioavailability, and avoidance of liver first-pass metabolism to appeal to patients with impaired kidney function and clinicians treating pruritus in CKD.

Clinical-Stage Advantage Position Avior as an early-stage, clinically focused partner for academic medical centers and nephrology clinics exploring novel pruritus therapies, leveraging non-dilutive NIH funding and upcoming data to de-risk early collaborations.

NTD Financing Signals Leverage the company’s NIH grant and recent pre-Series A traction to pursue strategic partnerships with specialty pharma companies, CROs, and KOLs in dermatology and nephrology for co-development, manufacturing support, or late-stage financing.

Tech & IP Leverage Highlight Speedit transmucosal film technology as a defensible platform for rapid onset and reduced metabolite burden; pursue licensing or collaboration opportunities around additional indications in pruritus or other neuromodulatory conditions with a similar delivery profile.

Market Readiness Capitalize on the ~$800 million addressable market for dialysis-related pruritus by aligning clinical development timelines with payer and patient advocacy groups, offering value propositions around quality of life, sleep improvement, and reduced excoriation in ESRD populations.